The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

A growing body of research is finding a robust link between diet and sleep quality. But it’s not just the usual suspects like ...

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

Sleep apnea, a condition that disrupts breathing during sleep, affects millions of people worldwide, especially adults over ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

A long-term study involving 400,000 Britons — published recently in Sleep Medicine journal — found that people who ate cheese had a 28% lower risk of having sleep apnea than those who didn’t. The data ...

Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...

both of which found that Zepbound helps reduce sleep apnea symptoms in some patients by aiding weight loss. Both studies monitored obese adults with moderate to severe sleep apnea over a 52-week ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...